Newcastle University spin-out FibroFind acquired by private equity firm

Newcastle University spin-out FibroFind acquired by private equity firm

The firm's methods - using real human tissue samples in the lab - give drug developers a more accurate picture of how their products work

FibroFind acquisition fuels ‘next phase of growth’

A biotechnology company specialising in pre-clinical testing for fibrotic diseases has been bought by a private equity firm to accelerate its global expansion. FibroFind, a 2019 spin-out from Newcastle University, has been acquired by Vespa Capital to expand its reach in drug development.  Specialising in testing treatments for liver, kidney and lung…